MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-373-1500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) issued its earnings results on Thursday, July, 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. View MediciNova's Earnings History.
When is MediciNova's next earnings date?
What price target have analysts set for MNOV?
1 equities research analysts have issued 1-year target prices for MediciNova's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 176.7% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Has MediciNova been receiving favorable news coverage?
News stories about MNOV stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MediciNova earned a news impact score of -2.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for MediciNova.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Innoviva (INVA) and Esperion Therapeutics (ESPR).
What other stocks do shareholders of MediciNova own?
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
- Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
- Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
- Ms. Carla Reyes, Chief Financial Officer (Age 47)
- Mr. John O'Neil CPA, Controller
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $7.95.
How big of a company is MediciNova?
MediciNova has a market capitalization of $344.71 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.
What is MediciNova's official website?
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
